CIRC (01763) announced that on December 10, 2025, its subsidiary Atom HighTech Co., Ltd., listed on the National Equities Exchange and Quotations, signed a patent transfer agreement and an industry-university-research collaboration agreement with Beijing Normal University in Beijing for the Fluorine [18F] Betazine project. Fluorine [18F] Betazine, jointly developed by Professor Cui Mengchao's team at Beijing Normal University and Atom HighTech, is a Class I innovative drug with full independent intellectual property rights, primarily used for early diagnosis of Alzheimer's disease. The drug has demonstrated significantly reduced non-specific uptake in white matter during clinical applications, outperforming similar FDA-approved products. This signing marks both a milestone in the prior collaboration between the two parties and a critical step in transforming scientific achievements into national strategic productivity through university-enterprise synergy. With the nuclear medicine industry entering a golden development period, Atom HighTech has emerged as a key player in the field, leveraging its deep industry expertise and distinctive strengths. Moving forward, the two parties will accelerate clinical translation of core innovations, foster talent development, and engage in global competition for next-generation nuclear medicine technologies, laying a solid foundation for China's high-quality growth in nuclear medicine.
Comments